ワクチンの世界市場:技術別(共役ワクチン、不活化ワクチン、弱毒化生ワクチン、トキソイドワクチン、組換え型ワクチン、その他)、適応症別(肺炎球菌性疾患、インフルエンザ、ヒトパピローマウイルス、髄膜炎菌性疾患、ロタウイルス、水痘、ジフテリア・百日咳・破傷風(DTP)、ポリオ、肝炎、麻疹・流行性耳下腺炎・風疹(MMR)、その他)、最終用途別(小児、成人、旅行者)

Allied Market Researchが発行した調査報告書(AMR8040492)
◆英語タイトル:Vaccines Market by Technology (Conjugate Vaccines, Inactivated Vaccines, Live Attenuated Vaccines, Toxoid Vaccines, Recombinant Vaccines, and Other Vaccines), Indication (Pneumococcal Disease; Influenza, Human Papilloma Virus; Meningococcal Disease; Rotavirus; Varicella; Diphtheria, Pertussis, and Tetanus (DTP); Polio; Hepatitis; Measles, Mumps, and Rubella (MMR); and Other Indications), and End Use (Pediatric Vaccines, Adult Vaccines, and Traveler Vaccines) - Global Opportunity Analysis and Industry Forecast, 2017-2023
◆商品コード:AMR8040492
◆発行会社(リサーチ会社):Allied Market Research
◆発行日:2017年5月
◆ページ数:240
◆レポート形式:英語 / PDF
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆産業分野:Pharmaceuticals
◆販売価格オプション(消費税別)
Single UserUSD5,540 ⇒換算¥609,400見積依頼/購入/質問フォーム
5 UserUSD6,903 ⇒換算¥759,312見積依頼/購入/質問フォーム
Enterprise UserUSD7,734 ⇒換算¥850,722見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はAllied Market Research社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。Allied Market Research社の概要及び新刊レポートはこちらでご確認いただけます。

本資料は、ワクチンの世界市場について調べ、ワクチンの世界規模、市場シェア、市場動向、市場環境、技術別(共役ワクチン、不活化ワクチン、弱毒化生ワクチン、トキソイドワクチン、組換え型ワクチン、その他)分析、適応症別(肺炎球菌性疾患、インフルエンザ、ヒトパピローマウイルス、髄膜炎菌性疾患、ロタウイルス、水痘、ジフテリア・百日咳・破傷風(DTP)、ポリオ、肝炎、麻疹・流行性耳下腺炎・風疹(MMR)、その他)分析、最終用途別(小児、成人、旅行者)分析、アメリカ市場規模、ヨーロッパ市場規模、アジア市場規模、日本市場規模、中国市場規模、関連企業情報などをまとめた調査レポートです。
・イントロダクション
・エグゼクティブサマリー
・ワクチンの世界市場概要
・ワクチンの世界市場環境
・ワクチンの世界市場動向
・ワクチンの世界市場規模
・ワクチンの世界市場:市場シェア
・ワクチンの世界市場:技術別(共役ワクチン、不活化ワクチン、弱毒化生ワクチン、トキソイドワクチン、組換え型ワクチン、その他)
・ワクチンの世界市場:適応症別(肺炎球菌性疾患、インフルエンザ、ヒトパピローマウイルス、髄膜炎菌性疾患、ロタウイルス、水痘、ジフテリア・百日咳・破傷風(DTP)、ポリオ、肝炎、麻疹・流行性耳下腺炎・風疹(MMR)、その他)
・ワクチンの世界市場:最終用途別(小児、成人、旅行者)
・ワクチンの世界市場:地域別市場規模・分析
・ワクチンの北米市場規模・予測
・ワクチンのアメリカ市場規模・予測
・ワクチンのヨーロッパ市場規模・予測
・ワクチンのアジア市場規模・予測
・ワクチンの日本市場規模・予測
・ワクチンの中国市場規模・予測
・関連企業情報
【レポートの概要】

Vaccine is a preparation of weak or killed pathogen to stimulate the immunity process of the body. The vaccine market is a segment under the pediatric drugs market, which accounts to 80% of the pharmaceutical drugs market. The demand for pediatric vaccines is the major driving force of the market. This is due to high birth rates in the developing countries that accounted to 97% in 2012. The major restraint is the side effects produced by the vaccines.
The opportunities of this market are the growing DNA vaccine market, which is easy to develop, low cost and few side effects. The challenges faced by this market are the development of vaccines. The vaccines are based on live organisms that have inherent variability. A small variation in the production process will significantly alter the biological property of the product.

The key players profiled in this report are: Abbott laboratories, Baxter International INC. GlaxoSmithKline PLC, Merck & CO. INC., Novartis AG, PFIZER, LG Life Sciences, Nippon Biologicals INC., Advaxis, Panacea biotec ltd.

KEY BENEFITS

The report analyzes the vaccines market which is a combination of pediatric and adult vaccine market.
The report provides in-depth analysis about types, applications and geography of the vaccine market
The report evaluates the key factors that prove to be drivers and restraints for the market
The report analyzes the vaccine market based on the various segments to forecast growth till 2020.
The report analyzes the market factors in various geographic regions to understand business opportunities

Key Market segment:
Global vaccines market by, Types

Attenuated vaccines
Inactivated vaccines
Conjugated vaccines
Recombinant vaccines
Subunit vaccine
Combination vaccines
Toxoid vaccines

Global vaccines market by, Applications

Therapeutic vaccines
Prophylactic vaccines
Based on diseases
Pneumococcal diseases
Influenza diseases
Pediatric polio
Adult booster vaccines
Travel related and other endemic diseases
HPV (human papillomavirus) disease
Rotavirus disease
Other diseases

Global vaccines market by, Geography

North America
Europe
Asia pacific
RoW

KEY AUDIENCES

Government health organization
Hospitals
Manufacturers of vaccines
Research institutes

【レポートの目次】

Chapter: 1 INTRODUCTION

1.1. REPORT DESCRIPTION
1.2. KEY BENEFITS
1.3. KEY MARKET SEGMENTS
1.4. RESEARCH METHODOLOGY

1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools & models

Chapter: 2 EXECUTIVE SUMMARY

2.1. CXO PERSPECTIVE

Chapter: 3 MARKET OVERVIEW

3.1. MARKET DEFINITION AND SCOPE
3.2. KEY FINDINGS

3.2.1. Top investment pockets
3.2.2. Top winning strategies

3.2.2.1. Competitive intelligence of companies and their strategies

3.3. PORTERS FIVE FORCES ANALYSIS
3.4. GOVERNMENT REGULATIONS

3.4.1. FDA
3.4.2. CE Mark
3.4.3. Therapeutic Goods Administration (TGA)
3.4.4. Ministry of Health, Labour and Welfare (MHLW)

3.5. MARKET SHARE ANALYSIS, 2016
3.6. VACCINE PRODUCT AND PIPELINE ANALYSIS
3.7. CLINICAL TRIALS BY KEY PLAYERS
3.8. MARKET DYNAMICS

3.8.1. Drivers

3.8.1.1. High prevalence of diseases
3.8.1.2. Increase in government focus on immunization programs
3.8.1.3. Emerging vaccines
3.8.1.4. Technological progress in vaccine administration

3.8.2. Restraints

3.8.2.1. Longer timelines required for vaccine production
3.8.2.2. High costs associated with the development of vaccines

3.8.3. Opportunity

3.8.3.1. High growth prospects in emerging markets

Chapter: 4 VACCINES MARKET, BY TECHNOLOGY

4.1. OVERVIEW

4.1.1. Market size and forecast

4.2. CONJUGATE VACCINES

4.2.1. Key market trends
4.2.2. Growth factors and opportunities
4.2.3. Market size and forecast

4.3. INACTIVATED VACCINES

4.3.1. Key market trends
4.3.2. Growth factors and opportunities
4.3.3. Market size and forecast

4.4. LIVE ATTENUATED VACCINES

4.4.1. Key market trends
4.4.2. Growth factors and opportunities
4.4.3. Market size and forecast

4.5. TOXOID VACCINES

4.5.1. Key market trends
4.5.2. Growth factors and opportunities
4.5.3. Market size and forecast

4.6. RECOMBINANT VACCINES

4.6.1. Key market trends
4.6.2. Growth factors and opportunities
4.6.3. Market size and forecast

4.7. OTHER VACCINES

4.7.1. Market size and forecast

Chapter: 5 VACCINES MARKET, BY END USE

5.1. OVERVIEW

5.1.1. Market size and forecast

5.2. PEDIATRIC VACCINES

5.2.1. Market size and forecast

5.3. ADULT VACCINES

5.3.1. Market size and forecast

5.4. TRAVELER VACCINES

5.4.1. Market size and forecast

Chapter: 6 VACCINES MARKET, BY INDICATION

6.1. OVERVIEW

6.1.1. Market size and forecast

6.2. PNEUMOCOCCAL DISEASE

6.2.1. Market size and forecast

6.3. INFLUENZA

6.3.1. Market size and forecast

6.4. HUMAN PAPILLOMA VIRUS

6.4.1. Market size and forecast

6.5. MENINGOCOCCAL DISEASE

6.5.1. Market size and forecast

6.6. ROTAVIRUS

6.6.1. Market size and forecast

6.7. VARICELLA

6.7.1. Market size and forecast

6.8. DIPHTHERIA, PERTUSSIS, AND TETANUS (DPT)

6.8.1. Market size and forecast

6.9. POLIO

6.9.1. Market size and forecast

6.10. HEPATITIS

6.10.1. Market size and forecast

6.11. MEASLES, MUMPS, AND RUBELLA (MMR)

6.11.1. Market size and forecast

6.12. OTHER INDICATIONS

6.12.1. Market size and forecast

Chapter: 7 VACCINES MARKET, BY REGION

7.1. OVERVIEW

7.1.1. Market size and forecast

7.2. NORTH AMERICA

7.2.1. Key market trends
7.2.2. Key growth factors and opportunities
7.2.3. Market size and forecast
7.2.4. U.S. market size and forecast
7.2.5. Canada market size and forecast
7.2.6. Mexico market size and forecast

7.3. EUROPE

7.3.1. Key market trends
7.3.2. Key growth factors and opportunities
7.3.3. Market size and forecast
7.3.4. UK market size and forecast
7.3.5. France market size and forecast
7.3.6. Germany market size and forecast
7.3.7. Italy market size and forecast
7.3.8. Spain market size and forecast
7.3.9. Rest of Europe market size and forecast

7.4. ASIA-PACIFIC

7.4.1. Key market trends
7.4.2. Key growth factors and opportunities
7.4.3. Market size and forecast
7.4.4. Japan market size and forecast
7.4.5. China market size and forecast
7.4.6. India market size and forecast
7.4.7. Australia market size and forecast
7.4.8. Rest of Asia-Pacific market size and forecast

7.5. LAMEA

7.5.1. Key market trends
7.5.2. Key growth factors and opportunities
7.5.3. Market size and forecast
7.5.4. Brazil market size and forecast
7.5.5. Argentina market size and forecast
7.5.6. Turkey market size and forecast
7.5.7. South Africa market size and forecast
7.5.8. Rest of LAMEA market size and forecast

Chapter: 8 COMPANY PROFILES

8.1. ASTELLAS PHARMA INC.

8.1.1. Company overview
8.1.2. Company snapshot
8.1.3. Product portfolio
8.1.4. Business performance
8.1.5. Key strategic moves and developments

8.2. ASTRAZENECA PLC (MEDIMMUNE, LLC)

8.2.1. Company overview
8.2.2. Company snapshot
8.2.3. Operating business segments
8.2.4. Product portfolio
8.2.5. Business performance
8.2.6. Key strategic moves and developments

8.3. CSL LIMITED

8.3.1. Company overview
8.3.2. Company snapshot
8.3.3. Operating business segments
8.3.4. Product portfolio
8.3.5. Business performance
8.3.6. Key strategic moves and developments

8.4. EMERGENT BIOSOLUTIONS, INC.

8.4.1. Company overview
8.4.2. Company snapshot
8.4.3. Operating business segments
8.4.4. Product portfolio
8.4.5. Business performance
8.4.6. Key strategic moves and developments

8.5. GLAXOSMITHKLINE PLC

8.5.1. Company overview
8.5.2. Company snapshot
8.5.3. Operating business segments
8.5.4. Product portfolio
8.5.5. Business performance
8.5.6. Key strategic moves and developments

8.6. JOHNSON & JOHNSON

8.6.1. Company overview
8.6.2. Company Snapshot
8.6.3. Operating business segments
8.6.4. Product portfolio
8.6.5. Business performance
8.6.6. Key strategic moves and developments

8.7. MERCK & CO., INC.

8.7.1. Company overview
8.7.2. Company snapshot
8.7.3. Operating business segments
8.7.4. Product portfolio
8.7.5. Business performance
8.7.6. Key strategic moves and developments

8.8. PFIZER INC.

8.8.1. Company overview
8.8.2. Company snapshot
8.8.3. Operating business segments
8.8.4. Product portfolio
8.8.5. Business performance
8.8.6. Key strategic moves and developments

8.9. SANOFI

8.9.1. Company overview
8.9.2. Company snapshot
8.9.3. Operating business segments
8.9.4. Product portfolio
8.9.5. Business performance
8.9.6. Key strategic moves and developments

8.10. SERUM INSTITUTE OF INDIA PVT. LTD.

8.10.1. Company overview
8.10.2. Company snapshot
8.10.3. Product portfolio
8.10.4. Key strategic moves and developments

TABLE 1. SELECT FDA AND ICH GUIDANCE DOCUMENTS RELEVANT TO VACCINE DEVELOPMENT
TABLE 2. LOT-RELEASE TESTING GUIDELINES
TABLE 3. TOP FIVE BEST SELLING VACCINE PRODUCTS, 2015 & 2022
TABLE 4. TOP FIVE R&D VACCINE PRODUCTS UNDER PIPELINE, 2015 & 2022
TABLE 5. GLOBAL VACCINES MARKET, BY TECHNOLOGY, 2016-2023 ($MILLION)
TABLE 6. CONJUGATE VACCINES MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 7. LIST OF COMMERCIAL INACTIVATED VACCINES
TABLE 8. INACTIVATED VACCINES MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 9. LIST OF COMMERCIAL LIVE ATTENUATED VACCINES
TABLE 10. LIVE ATTENUATED VACCINES MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 11. TOXOID VACCINES MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 12. LIST OF COMMERCIAL RECOMBINANT VACCINES
TABLE 13. RECOMBINANT VACCINES MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 14. OTHER VACCINES MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 15. GLOBAL VACCINES MARKET, BY END USE, 2016-2023 ($MILLION)
TABLE 16. PEDIATRIC VACCINES MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 17. RECOMMENDED IMMUNIZATION SCHEDULE, U.S., 2017
TABLE 18. ADULT VACCINES MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 19. TRAVELER VACCINES MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 20. GLOBAL VACCINES MARKET, BY INDICATION, 2016-2023 ($MILLION)
TABLE 21. COMPANY PRODUCT ANALYSIS OF PNEUMOCOCCAL VACCINES IN U.S.
TABLE 22. VACCINES MARKET FOR PNEUMOCOCCAL DISEASE, BY REGION, 2016-2023 ($MILLION)
TABLE 23. INFLUENZA VACCINE RECOMMENDATIONS BY CDC, 2016-2017
TABLE 24. COMPANY PRODUCT ANALYSIS OF INFLUENZA VACCINES IN U.S.
TABLE 25. VACCINES MARKET FOR INFLUENZA, BY REGION, 2016-2023 ($MILLION)
TABLE 26. HUMAN PAPILLOMA VIRUS RECOMMENDATIONS BY CDC, 2016-2017
TABLE 27. COMPANY PRODUCT ANALYSIS OF HUMAN PAPILLOMA VACCINES IN U.S.
TABLE 28. VACCINES MARKET FOR HUMAN PAPILLOMA VIRUS, BY REGION, 2016-2023 ($MILLION)
TABLE 29. COMPANY PRODUCT ANALYSIS OF MENINGOCOCCAL VACCINES IN U.S.
TABLE 30. MENINGOCOCCAL DISEASE VACCINES MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 31. COMPANY PRODUCT ANALYSIS OF ROTAVIRUS VACCINES IN U.S.
TABLE 32. ROTAVIRUS VACCINE RECOMMENDATIONS BY CDC, 2016-2017
TABLE 33. VACCINES MARKET FOR ROTAVIRUS, BY REGION, 2016-2023 ($MILLION)
TABLE 34. COMPANY PRODUCT ANALYSIS OF VARICELLA VACCINES IN U.S.
TABLE 35. VACCINES MARKET FOR VARICELLA, BY REGION, 2016-2023 ($MILLION)
TABLE 36. COMPANY PRODUCT ANALYSIS OF DPT VACCINES IN U.S.
TABLE 37. VACCINES MARKET FOR DPT, BY REGION, 2016-2023 ($MILLION)
TABLE 38. COMPANY PRODUCT ANALYSIS OF POLIO VACCINES IN U.S.
TABLE 39. VACCINES MARKET FOR POLIO, BY REGION, 2016-2023 ($MILLION)
TABLE 40. COMPANY PRODUCT ANALYSIS OF HEPATITIS VACCINES IN U.S.
TABLE 41. VACCINES MARKET FOR HEPATITIS, BY REGION, 2016-2023 ($MILLION)
TABLE 42. COMPANY PRODUCT ANALYSIS OF MMR VACCINES IN U.S.
TABLE 43. VACCINES MARKET FOR MMR, BY REGION, 2016-2023 ($MILLION)
TABLE 44. COMPANY PRODUCT ANALYSIS OF OTHER VACCINES IN U.S.
TABLE 45. VACCINES MARKET FOR OTHER INDICATIONS, BY REGION, 2016-2023 ($MILLION)
TABLE 46. VACCINES MARKET, BY REGION ($MILLION)
TABLE 47. NORTH AMERICA VACCINES MARKET, BY COUNTRY ($MILLION)
TABLE 48. NORTH AMERICA VACCINES MARKET, BY TECHNOLOGY ($MILLION)
TABLE 49. NORTH AMERICA VACCINES MARKET, BY INDICATION ($MILLION)
TABLE 50. NORTH AMERICA VACCINES MARKET, BY END USE ($MILLION)
TABLE 51. EUROPE VACCINES MARKET, BY COUNTRY ($MILLION)
TABLE 52. EUROPE VACCINES MARKET, BY TECHNOLOGY ($MILLION)
TABLE 53. EUROPE VACCINES MARKET, BY INDICATION ($MILLION)
TABLE 54. EUROPE VACCINES MARKET, BY END USE ($MILLION)
TABLE 55. ASIA-PACIFIC VACCINES MARKET, BY COUNTRY ($MILLION)
TABLE 56. ASIA-PACIFIC VACCINES MARKET, BY TECHNOLOGY ($MILLION)
TABLE 57. ASIA-PACIFIC VACCINES MARKET, BY INDICATION ($MILLION)
TABLE 58. ASIA-PACIFIC VACCINES MARKET, BY END USE ($MILLION)
TABLE 59. LAMEA VACCINES MARKET, BY COUNTRY ($MILLION)
TABLE 60. LAMEA VACCINES MARKET, BY TECHNOLOGY ($MILLION)
TABLE 61. LAMEA VACCINES MARKET, BY INDICATION ($MILLION)
TABLE 62. LAMEA VACCINES MARKET, BY END USE ($MILLION)
TABLE 63. ASTELLAS: COMPANY SNAPSHOT
TABLE 64. ASTELLAS: PRODUCT PORTFOLIO
TABLE 65. ASTRAZENECA: COMPANY SNAPSHOT
TABLE 66. ASTRAZENECA: OPERATING SEGMENTS
TABLE 67. ASTRAZENECA: PRODUCT PORTFOLIO
TABLE 68. CSL: COMPANY SNAPSHOT
TABLE 69. CSL: OPERATING SEGMENTS
TABLE 70. CSL: PRODUCT PORTFOLIO
TABLE 71. EMERGENT BIOSOLUTIONS: COMPANY SNAPSHOT
TABLE 72. EMERGENT BIOSOLUTIONS: OPERATING SEGMENTS
TABLE 73. EMERGENT BIOSOLUTIONS: PRODUCT PORTFOLIO
TABLE 74. GSK: COMPANY SNAPSHOT
TABLE 75. GSK: OPERATING SEGMENTS
TABLE 76. GSK: PRODUCT PORTFOLIO
TABLE 77. J&J: COMPANY SNAPSHOT
TABLE 78. J&J: OPERATING SEGMENTS
TABLE 79. J&J: PRODUCT PORTFOLIO
TABLE 80. MERCK: COMPANY SNAPSHOT
TABLE 81. MERCK: OPERATING SEGMENTS
TABLE 82. MERCK: PRODUCT PORTFOLIO
TABLE 83. PFIZER: COMPANY SNAPSHOT
TABLE 84. PFIZER: OPERATING SEGMENTS
TABLE 85. PFIZER: PRODUCT PORTFOLIO
TABLE 86. SANOFI: COMPANY SNAPSHOT
TABLE 87. SANOFI: OPERATING SEGMENTS
TABLE 88. SANOFI: PRODUCT PORTFOLIO
TABLE 89. SERUM INSTITUTE OF INDIA: COMPANY SNAPSHOT
TABLE 90. SERUM INSTITUTE OF INDIA: PRODUCT PORTFOLIO

FIGURE 1. SNAPSHOT OF GLOBAL VACCINES MARKET, 2017-2023
FIGURE 2. SNAPSHOT OF GLOBAL VACCINES, BY REGION
FIGURE 3. MARKET SEGMENTATION
FIGURE 4. TOP INVESTMENT POCKETS
FIGURE 5. TOP WINNING STRATEGIES, 2014-2017 (%)
FIGURE 6. TOP WINNING STRATEGIES: NATURE AND TYPE
FIGURE 7. TOP COMPANIES AND THEIR STRATEGIES
FIGURE 8. DETAILED STRUCTURE OF COMPANIES AND TYPE OF STRATEGIES
FIGURE 9. DETAILED STRUCTURE OF COMPANIES AND NATURE OF STRATEGIES
FIGURE 10. BARGAINING POWER OF BUYERS
FIGURE 11. BARGAINING POWER OF SUPPLIERS
FIGURE 12. THREAT OF NEW ENTRANTS
FIGURE 13. THREAT OF SUBSTITUTION
FIGURE 14. COMPETITIVE RIVALRY
FIGURE 15. FDA REGULATION ANALYSIS
FIGURE 16. VACCINE APPROVAL PROCESS
FIGURE 17. MARKET SHARE ANALYSIS, 2016
FIGURE 18. CLINICAL TRIALS FOR VACCINES MARKET BY TOP PLAYERS (%)
FIGURE 19. VACCINE CLINICAL TRIAL DEVELOPMENT FOR DIFFERENT INDICATION
FIGURE 20. RESTRAINTS AND DRIVERS
FIGURE 21. VACCINE DEVELOPMENT CYCLE
FIGURE 22. GLOBAL VACCINES MARKET: TECHNOLOGY SEGMENTATION
FIGURE 23. STATISTICAL ANALYSIS OF APPLICATION OF CONJUGATE VACCINES IN THE PREVENTION OF DISEASES
FIGURE 24. GLOBAL VACCINES MARKET: END USE SHARE ANALYSIS, 2016
FIGURE 25. TYPES OF TRAVEL VACCINES IN UK
FIGURE 26. PNEUMOCOCCAL DISEASES AMONG CHILDREN AGED <5 YEARS IN U.S.
FIGURE 27. U.S. VACCINES MARKET, 2016-2023 ($MILLION)
FIGURE 28. CANADA VACCINES MARKET, 2016-2023 ($MILLION)
FIGURE 29. MEXICO VACCINES MARKET, 2016-2023 ($MILLION)
FIGURE 30. UK VACCINES MARKET, 2016-2023 ($MILLION)
FIGURE 31. FRANCE VACCINES MARKET, 2016-2023 ($MILLION)
FIGURE 32. GERMANY VACCINES MARKET, 2016-2023 ($MILLION)
FIGURE 33. ITALY VACCINES MARKET, 2016-2023 ($MILLION)
FIGURE 34. SPAIN VACCINES MARKET, 2016-2023 ($MILLION)
FIGURE 35. REST OF EUROPE VACCINES MARKET, 2016-2023 ($MILLION)
FIGURE 36. JAPAN VACCINES MARKET, 2016-2023 ($MILLION)
FIGURE 37. CHINA VACCINES MARKET, 2016-2023 ($MILLION)
FIGURE 38. INDIA VACCINES MARKET, 2016-2023 ($MILLION)
FIGURE 39. AUSTRALIA VACCINES MARKET, 2016-2023 ($MILLION)
FIGURE 40. REST OF ASIA PACIFIC VACCINES MARKET, 2016-2023 ($MILLION)
FIGURE 41. BRAZIL VACCINES MARKET, 2016-2023 ($MILLION)
FIGURE 42. ARGENTINA VACCINES MARKET, 2016-2023 ($MILLION)
FIGURE 43. TURKEY VACCINES MARKET, 2016-2023 ($MILLION)
FIGURE 44. SOUTH AFRICA VACCINES MARKET, 2016-2023 ($MILLION)
FIGURE 45. REST OF LAMEA VACCINES MARKET, 2016-2023 ($MILLION)
FIGURE 46. ASTELLAS: NET SALES, 2014-2016 ($MILLION)
FIGURE 47. ASTELLAS: REVENUE SHARE BY GEOGRAPHY, 2016 (%)
FIGURE 48. ASTRAZENECA: NET SALES, 2014-2016 ($MILLION)
FIGURE 49. ASTRAZENECA: REVENUE SHARE BY GEOGRAPHY, 2016 (%)
FIGURE 50. CSL: NET SALES, 2014-2016 ($MILLION)
FIGURE 51. CSL: REVENUE SHARE BY PRODUCT, 2016 (%)
FIGURE 52. CSL: REVENUE SHARE BY GEOGRAPHY, 2016 (%)
FIGURE 53. EMERGENT: NET SALES, 2014-2016 ($MILLION)
FIGURE 54. GSK: NET SALES, 2014-2016 ($MILLION)
FIGURE 55. GSK: REVENUE SHARE BY SEGMENT, 2016 (%)
FIGURE 56. GSK: REVENUE SHARE BY GEOGRAPHY, 2016 (%)
FIGURE 57. J&J: NET SALES, 2014-2016 ($MILLION)
FIGURE 58. J&J: REVENUE SHARE BY SEGMENT, 2016 (%)
FIGURE 59. J&J: REVENUE SHARE BY GEOGRAPHY, 2016 (%)
FIGURE 60. MERCK: NET SALES, 2014-2016 ($MILLION)
FIGURE 61. MERCK: REVENUE SHARE BY SEGMENT, 2016 (%)
FIGURE 62. MERCK: REVENUE SHARE BY GEOGRAPHY, 2016 (%)
FIGURE 63. PFIZER: NET SALES, 2014-2016 ($MILLION)
FIGURE 64. PFIZER: REVENUE SHARE BY SEGMENT, 2016 (%)
FIGURE 65. PFIZER: REVENUE SHARE BY GEOGRAPHY, 2016 (%)
FIGURE 66. SANOFI: NET SALES, 2014-2016 ($MILLION)
FIGURE 67. SANOFI: REVENUE SHARE BY SEGMENT, 2016 (%)
FIGURE 68. SANOFI: REVENUE SHARE BY GEOGRAPHY, 2016 (%)

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ ワクチンの世界市場:技術別(共役ワクチン、不活化ワクチン、弱毒化生ワクチン、トキソイドワクチン、組換え型ワクチン、その他)、適応症別(肺炎球菌性疾患、インフルエンザ、ヒトパピローマウイルス、髄膜炎菌性疾患、ロタウイルス、水痘、ジフテリア・百日咳・破傷風(DTP)、ポリオ、肝炎、麻疹・流行性耳下腺炎・風疹(MMR)、その他)、最終用途別(小児、成人、旅行者)(Vaccines Market by Technology (Conjugate Vaccines, Inactivated Vaccines, Live Attenuated Vaccines, Toxoid Vaccines, Recombinant Vaccines, and Other Vaccines), Indication (Pneumococcal Disease; Influenza, Human Papilloma Virus; Meningococcal Disease; Rotavirus; Varicella; Diphtheria, Pertussis, and Tetanus (DTP); Polio; Hepatitis; Measles, Mumps, and Rubella (MMR); and Other Indications), and End Use (Pediatric Vaccines, Adult Vaccines, and Traveler Vaccines) - Global Opportunity Analysis and Industry Forecast, 2017-2023)]についてメールでお問い合わせはこちらでお願いします。


◆H&Iグローバルリサーチのお客様(例)◆